Quorum-Sensing-Regulated Bactobolin Production by Burkholderia thailandensis E264 by Seyedsayamdost, Mohammad R. et al.
Quorum-Sensing-Regulated Bactobolin
Production by Burkholderia
thailandensis E264
Mohammad R. Seyedsayamdost,
† Josephine R. Chandler,
‡
Joshua A. V. Blodgett,
† Patricia S. Lima,
‡ Breck A. Duerkop,
‡
Ken-Ichi Oinuma,
‡ E. Peter Greenberg,*
,‡ and Jon Clardy*
,†
Department of Biological Chemistry and Molecular Pharmacology, HarVard Medical
School, Boston, Massachusetts 02115, and Department of Microbiology, UniVersity of
Washington School of Medicine, Seattle, Washington 98195
jon_clardy@hms.harVard.edu; epgreen@u.washington.edu
Received November 29, 2009
ABSTRACT
Bacterial acyl-homoserine lactones upregulated an uncharacterized gene cluster (bta)i nBurkholderia thailandensis E264 to produce an
uncharacterized polar antibiotic. The antibiotic is identiﬁed as a mixture of four bactobolins. Annotation of the bta cluster allows us to propose
a biosynthetic scheme for bactobolin and reveals unusual enzymatic reactions for further study.
Sequenced bacterial genomes are appearing at an ever-
increasing rate, and they document both the remarkable
metabolic potential of these organisms and our limited ability
to access this potential. The sequences reported thus far have
revealed many more molecules whose existence can be
inferred from genomic analysis than molecules whose
existence has been established in the laboratory.
1 Many of
these metabolites likely remain cryptic because their produc-
tion is regulated, and the regulatory factors are not known.
Burkholderia thailandensis E264, a Gram-negative bacillus
that has become a model organism for its more virulent
relatives, has a completely sequenced genome that contains
at least 12 unassigned polyketide synthase (PKS) and/or non-
ribosomal peptide synthase (NRPS) clusters, which are being
extensively studied.
2 Many behaviors of Gram-negative
bacteria are regulated in a population-density-dependent
fashion by acyl-homoserine lactones (Ac-HSLs).
3 Recently,
Duerkop et al. examined the regulation of antibiotic produc-
tion in B. thailandensis E264 by Ac-HSL and showed that
the two Ac-HSLs produced by the BtaR2-BtaI2 signaling
system regulated the production of a polar antibiotic of
unknown structure.
4 Using mutational analysis, they were
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Published on Web 01/22/2010able to deﬁne the biosynthetic locus (bta cluster) of the
antibiotic.
4 Herein, we report the structure of the antibiotic
and establish its activity against selected bacterial pathogens.
Annotation of the biosynthetic cluster allows us to propose
a biosynthetic scheme that serves as a starting point for
examining the unusual reactions involved.
To isolate the antibiotic, B. thailandensis was cultivated
as previously reported.
4 The antibiotic’s highly polar, am-
photeric nature and its optimal production in rich media (LB)
necessitated unusual chromatographic steps (see Supporting
Information). Using activity-guided fractionation against B.
subtilis 3610, four active compounds were puriﬁed, and their
structures were elucidated by 1-D/2-D NMR (Figures S1-S6
and Tables S1-S4 in Supporting Information) HR-MS, and
MS/MS (Table S5) methods. The antibiotics belong to the
bactobolin/actinobolin family (Figure 1).
5 The structures of
bactobolins A-C have previously been characterized by
X-ray crystallography and chemical analysis.
6,7 Bactobolin
D is new and likely a biosynthetic precursor to bactobolins
A-C. The stereochemistry is based on [R]D comparisons
(Table S5), J coupling, and ROESY spectral analyses, which
conﬁrm the axial-axial relationship of protons H5/H10 and
H5/H6, the axial-equatorial relationship of H10/H4, and the
homoallylic coupling between H10 and H7ax (Figures
S1-S6).
5,6 The stereochemistry of the Ala residue(s) was
conﬁrmed by acid hydrolysis followed by Marfey’s analysis
(see Supporting Information).
8
Bactobolins have several interesting structural features. As
suggested by the bta cluster, they are NRPS-PKS hybrids
containing a di- or tripeptide fused to a C6-polyketide. The
fusion occurs at the carboxyl group of 3-hydroxy-4,4-
dichlorovaline (OH-Cl2-Val), an unnatural amino acid with
unknown biosynthesis that is thus far limited to the bacto-
bolins. The enol lactone likely mimics a carboxyl group,
allowing bactobolins to enter the cell via di- and tripeptide
transporters.
9 Bactobolins differ from actinobolin, an anti-
biotic identiﬁed from Streptomyces griseoViridis, in that the
OH-Cl2-Val residue is replaced by Thr.
5a This switch renders
actinobolin 21-fold, 1000-fold, and 900-fold less active than
bactobolin in E. coli kill assays, in vitro inhibition of
translation, and murine antitumor activity, respectively.
10
The identiﬁcation of bactobolin and its link to the bta
cluster allows us to propose a scheme for its biosynthesis.
The modular 44 kb PKS/NRPS cluster is highly fragmented
with product(s) inconsistent with the co-linearity rule (Figure
2A). On the basis of short intergenic sequences and a single
identiﬁable Shine-Dalgarno sequence, the translation of btaK-
btaS appears to occur from one polycistronic mRNA. The
cluster contains six distinct elements: genes involved in regula-
tion (orange), metabolite/product transporters (green), synthesis
of OH-Cl2-Val (gray), Ala-Ala (light gray) and the C6 polyketide
and related reactions (blue), tailoring reactions (brown), and
genes of unknown function (white, Figure 2A). Results of
homology searches and other bioinformatic analyses (Table S6)
lead us to propose the model in Figure 2B.
Annotation of the bta cluster provides a biosynthetic route
for OH-Cl2-Val and its insertion into the NRPS/PKS transfer
line (Figure 2B, inset). Its biosynthesis requires both dichlo-
rination and hydroxylation reactions. Dichlorination likely
involves BtaC, a Fe-dependent chlorinase (57% identical to
CytC3). BtaC contains an Ala residue, typical for Fe-
dependent chlorinases, in place of the carboxylate group that
usually occupies the facial triad and coordinates Fe in R-KG-
dependent oxygenases.
11 Hydroxylation of Val (or Cl2-Val)
could be catalyzed by either BtaA or BtaU, both non-heme
Fe-dependent dioxygenases, or even by BtaC as recent
studies have delineated the requirements for Cl versus OH
insertion by these enzymes.
12 BtaC is ﬂanked by two free-
standing thiolation (T) domains, where BtaB lacks the typical
GXDS(L/I) sequence motif and may be inactive.
13 Thus,
BtaD is likely the active T domain and may be primed with
Val by BtaE, a Val-speciﬁc, stand-alone adenylation (A)
domain. BtaH contains a GXCX(G/S) motif and likely acts
as an CmaE-like transacylase,
14 by shuttling the assembled
OH-Cl2-Val from one T domain to another within the NRPS
assembly line (Figure 2B, inset).
BtaK and BtaN are NRPSs with the domain architecture
shown in Figure 2B. The ﬁrst condensation (C) domain in
BtaK does not contain the conserved active site motif
(HHX3DG) and is likely inactive.
13 Its A domain bears higher
homology to Gly-speciﬁc domains, but no Gly-bearing
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Figure 1. Bactobolins characterized in this work.
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Ala-Ala-(OH-Cl2-Val) tripeptide (2). This is subsequently
condensed to an acetyl group originating from malonyl CoA
catalyzed by the ketosynthase (KS) domain of BtaO (3),
followed by another acetyl group addition and ketoreduction
(KR) by BtaM to give 4 (Figure 2B).
The ﬁnal C2 unit may be added by BtaL, yielding 5. BtaL
contains a non-canonical KR domain that is similar to short
chain dehydrogenases (SDR). There is a 300 amino acid region
between the AT and SDR domains with no recognizable
sequence homology. The ensuing plausible reactions that may
yield bactobolin D, aldol condensation between OH-Cl2-Val and
the ﬁnal malonyl-CoA unit and elimination of water to give 6,
followed by reduction of the resulting R, -unsaturated ketone
to generate the enol moiety (Figure 2B), lack clear precedents
at this time. These reactions may be performed by the SDR
domain in BtaL and the adjoining 300 amino acid region.
15,16
BtaS, a predicted type II thioesterase, may be involved in
generation of the lactone. Alternatively, lactonization could
be carried out by BtaP, a predicted  -lactamase, in ac-
cordance with recent studies by Awakawa et al.
17 Biochemi-
cal studies are in progress to discern between these options
and to examine the biosynthetic model in detail.
The bta cluster appears to provide an indication of how
four analogues are biosynthesized by one cluster.
18 The
hydroxyl group at C5 may be inserted by BtaA or BtaU (see
above). BtaQ and BtaJ bear high identity to an acetyltrans-
ferase and an oligopeptidase, respectively. Indeed acetylated
bactobolins have previously been reported.
6 N-Acetyl pep-
tides are good substrates for oligopeptidases,
19 which could
cleave N-acetyl-bactobolin B or D, generated by BtaQ, to
yield bactobolin A or C, respectively. Thus, a promiscuous
hydroxylase and an oligopeptidase may generate three
additional congeners from bactobolin D.
Bta-based bioinformatic searches for its relatives show that
bta is widespread in and conﬁned to the Burkholderia genus
(Figure 3). This suggests that the biosynthesis of OH-Cl2-
Val and its incorporation into the actinobolin framework
evolved only in the Burkholderia lineage. The bta cluster is
found in avirulent and virulent members of Burkholderia,
including the important human pathogen B. pseudomallei.
20
(15) Secondary structure predictions show that this 300 amino acid region
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involved in erythromycin biosynthesis stabilizes an enolate intermediate,
which is required for enzymatic aldol reactions proposed herein. See ref
16.
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Figure 2. (A) Schematic of the bactobolin biosynthetic cluster detailing genes btaA through btaU. (B) Proposed biosynthetic scheme for
bactobolin D. Note that the aldol condensation (ALC) and thioesterase (TE) reactions are not assigned to a speciﬁc protein or domain. See
text for details. Inset, proposed biosynthesis of OH-Cl2-Val and its subsequent transfer to the NRPS/PKS assembly line.
Figure 3. Results of a bta-based bioinformatic search using the
protein database available on http://img.jgi.doe.gov. The clusters
with signiﬁcant homology are exclusively from sequenced Burkhold-
eria strains. Only the top six results of ﬁnished sequences are shown.
718 Org. Lett., Vol. 12, No. 4, 2010Deciphering the role of bactobolin in the quorum sensing
(QS) hierarchy will be important in understanding its
ecological function and the mechanism of pathogenesis
within virulent Burkholderia strains.
3,20
To begin to test the functional predictions above, muta-
tional and biochemical analyses have been carried out to
examine the export of bactobolin as a means of host
resistance. We investigated a QS-defective mutant, which
does not express btaK-btaS and thus does not produce
bactobolin.
4 Addition of exogenous bactobolin showed that
the mutant was resistant indicating that the resistance genes
lie outside of this region (Tables S7 and S8 in Supporting
Information).
21 BtaT is predicted to be a drug resistance
transporter and may be involved in the export of bactobolin.
To examine its function, an unmarked btaT mutation was
generated (see Supporting Information). Cultivation of this
mutant under the same conditions as above for 12 or 24 h
showed that export of bactobolin was reduced 18-fold or 10-
fold, respectively, relative to wt, supporting the role proposed
for BtaT.
22 The btaT mutant was resistant to bactobolin,
indicating additional pathways for its export, and that
resistance is not dependent on btaT (Figure 4).
23
To test the potency of bactobolins, antibiotic assays were
carried out against the human pathogens MRSA, VRE, and V.
parahemolyticus and against B. subtilis and E. coli (Table 1).
The results show that bactobolins A and B, which contain
the hydroxyl group at C5, are more potent than bactobolins
C and D. Bactobolin D is the weakest analogue. Bactobolins
A and B are potent antibiotics against MRSA and V.
parahemolyticus with MICs < 1 µg/mL. Bactobolin C is also
effective against these strains, though to a lesser extent. All
three analogues displayed low activity against VRE.
In summary, we have shown that the QS-regulated
antibiotic produced by B. thailandensis consists of four
bactobolins, of which two are potent antibiotics against
human pathogens. Analysis of the bta cluster has allowed
us to propose a biosynthetic scheme with several intriguing
features: the biosynthesis of a unique OH-Cl2-Val analogue,
an unusual acyltransferase reaction to introduce OH-Cl2-Val
into the assembly line, and a set of reactions to generate an
enol lactone functionality that is poorly-studied in the context
of PKS reactions. The genetic accessibility of B. thailan-
densis and a plausible biosynthetic model will facilitate
exploration of bactobolin biosynthesis.
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Figure 4. Ion-extracted LC-MS trace of the culture supernatants
of wt B. thailandensis versus those of the btaT and btaK deletion
mutants after 24 h of growth. The starred peaks correspond to
bactobolin B. The amount analyzed for the btaK/btaT mutants was
3-fold that of wt. See Supporting Information for details.
Table 1. Minimum Inhibitory Concentration (MIC, µg/mL)
a of
Bactobolins A, B, C, or D against Selected Bacterial Strains
strains A B C D
S. aureus COL (MRSA) 0.78 0.29 6.25 37.5
E. faecalis V583 (VRE) >25 25 >25 nd
b
V. parahemolyticus LM5674 0.20 0.20 1.56 nd
b
B. subtilis 3610 1.56 0.39 12.5 100
E. coli ATCC25922 6.25 1.56 25 >100
a MICs were determined according to the CLSI assay (see Supporting
Information). Values are the average from two independent experiments.
b nd ) not determined.
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